CN105228613A - 超纯的四氢大麻酚-11-羧酸 - Google Patents

超纯的四氢大麻酚-11-羧酸 Download PDF

Info

Publication number
CN105228613A
CN105228613A CN201480020828.1A CN201480020828A CN105228613A CN 105228613 A CN105228613 A CN 105228613A CN 201480020828 A CN201480020828 A CN 201480020828A CN 105228613 A CN105228613 A CN 105228613A
Authority
CN
China
Prior art keywords
acid
receptor
affinity
fold
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480020828.1A
Other languages
English (en)
Chinese (zh)
Inventor
M·泰珀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corbus Pharmaceuticals Inc
Original Assignee
Corbus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corbus Pharmaceuticals Inc filed Critical Corbus Pharmaceuticals Inc
Priority to CN201911271506.5A priority Critical patent/CN110946854A/zh
Publication of CN105228613A publication Critical patent/CN105228613A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201480020828.1A 2013-02-12 2014-02-12 超纯的四氢大麻酚-11-羧酸 Pending CN105228613A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911271506.5A CN110946854A (zh) 2013-02-12 2014-02-12 超纯的四氢大麻酚-11-羧酸

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361763630P 2013-02-12 2013-02-12
US61/763,630 2013-02-12
US201361837743P 2013-06-21 2013-06-21
US61/837,743 2013-06-21
PCT/US2014/016050 WO2014127016A2 (en) 2013-02-12 2014-02-12 Ultrapure tetrahydrocannabinol-11-oic acids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201911271506.5A Division CN110946854A (zh) 2013-02-12 2014-02-12 超纯的四氢大麻酚-11-羧酸

Publications (1)

Publication Number Publication Date
CN105228613A true CN105228613A (zh) 2016-01-06

Family

ID=51354671

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480020828.1A Pending CN105228613A (zh) 2013-02-12 2014-02-12 超纯的四氢大麻酚-11-羧酸
CN201911271506.5A Pending CN110946854A (zh) 2013-02-12 2014-02-12 超纯的四氢大麻酚-11-羧酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201911271506.5A Pending CN110946854A (zh) 2013-02-12 2014-02-12 超纯的四氢大麻酚-11-羧酸

Country Status (9)

Country Link
US (8) US20150141501A1 (enExample)
EP (2) EP2956133A4 (enExample)
JP (3) JP6689078B2 (enExample)
KR (2) KR20160002709A (enExample)
CN (2) CN105228613A (enExample)
AU (2) AU2014216440B2 (enExample)
BR (1) BR112015019180A8 (enExample)
CA (1) CA2900982C (enExample)
WO (1) WO2014127016A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109715152A (zh) * 2016-04-29 2019-05-03 柯巴斯医药有限公司 医治感染的方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6689078B2 (ja) 2013-02-12 2020-04-28 コーバス ファーマシューティカルズ インク． 超高純度なテトラヒドロカンナビノール−１１−酸
EP3481371A1 (en) * 2016-07-11 2019-05-15 Intec Pharma Ltd. Oral gastroretentive formulations and uses thereof
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
US20210284621A1 (en) * 2018-05-31 2021-09-16 Corbus Pharmaceuticals, Inc. Cannabinoids and uses thereof
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
US20200121614A1 (en) * 2018-10-18 2020-04-23 Bluegrass Farmacueticals, LLC Cannabinoid-infused transparent hydrogel skin patch
WO2020183456A1 (en) * 2019-03-10 2020-09-17 Bol Pharma Ltd. Cannabinoid combinations for treating chronic pain in dialysis patients
JP2022551863A (ja) 2019-10-11 2022-12-14 コーバス ファーマシューティカルズ インコーポレーテッド アジュレミン酸の組成物及びその使用
US20220023253A1 (en) * 2020-07-21 2022-01-27 Np Pharma Holdings, Llc Cannabinoid Compositions and Methods for Treating Joint Pain and Inflammation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110827A1 (en) * 2002-12-04 2004-06-10 Haim Aviv High enantiomeric purity dexanabinol for pharmaceutical compositions
US20040143126A1 (en) * 2001-03-07 2004-07-22 Webster G. R. Barrie Conversion of cbd to delta8-thc and delta9-thc
US20040186166A1 (en) * 2002-12-19 2004-09-23 Burstein Sumner H. Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
US20050009903A1 (en) * 2003-06-10 2005-01-13 Martin Billy R. CB2-selective cannabinoid analogues
US20100035978A1 (en) * 2005-11-01 2010-02-11 Gw Pharma Limited Combination of cannabinoids for the treatment of peripheral neuropathic pain
US20120309820A1 (en) * 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2186485B (en) 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
US5338753A (en) 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US8586767B2 (en) 1999-03-22 2013-11-19 Craig Rick Travis Method for treatment of HIV and diseases of immune dysregulation
US6974835B2 (en) 2000-05-17 2005-12-13 Indevus Pharmaceuticals, Inc. Methods for decreasing cell proliferation based on (3r,4r)-Δ8-tetrahydrocannabinol-11-oic acids
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
AU2003302578A1 (en) * 2002-12-04 2004-06-23 Pharmos Corporation High enantiomeric purity dexanabinol for pharmaceutical compositions
US7413748B2 (en) 2002-12-13 2008-08-19 Purdue Pharma L.P. Transdermal buprenorphine to treat pain in sickle cell crisis
US20050070596A1 (en) 2003-05-12 2005-03-31 David Baker Methods for treatment of inflammatory diseases using CT-3 or analogs thereof
AU2006240490A1 (en) 2005-04-21 2006-11-02 Paladin Labs (Barbados) Inc. Process for the preparation of ultrapure 4-methylprazole
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070037873A1 (en) 2005-08-08 2007-02-15 Zurier Robert B Airway remodeling treatments
US20070060639A1 (en) 2005-09-09 2007-03-15 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
WO2007055806A1 (en) * 2005-10-31 2007-05-18 Indevus Pharmaceuticals, Inc. Anti-emetic uses of (3r,4r)-δ8-tetrahydrocannabinol-11-oic acids
DK1903866T3 (en) 2005-11-07 2016-07-25 Murty Pharmaceuticals Inc Improved release of tetrahydrocannabinol
US20080054300A1 (en) * 2006-06-30 2008-03-06 Philip Gene Nikkel Body contact structure and method for the reduction of drain lag and gate lag in field effect transistors
US8058227B2 (en) 2006-10-03 2011-11-15 Medical University Of South Carolina Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD
US8044071B2 (en) 2007-10-18 2011-10-25 Abbott Laboratories Method for reducing side effects of CB2 receptor agonist therapy using a combination of a selective CB2 receptor agonist and a selective CB1 receptor antagonist
US9192598B2 (en) 2008-06-25 2015-11-24 University Of North Texas Health Science Center At Fort Worth Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
US20130338220A1 (en) 2010-10-05 2013-12-19 Mark Tepper Compositions, dosages, and methods of using tetrahydrocannabinol derivatives
JP6689078B2 (ja) 2013-02-12 2020-04-28 コーバス ファーマシューティカルズ インク． 超高純度なテトラヒドロカンナビノール−１１−酸
US20150328198A1 (en) 2014-05-16 2015-11-19 The University Of North Carolina At Chapel Hill Methods of treating methicillin-resistant staphylococcus aureus (mrsa) using ppar-gamma agonists

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040143126A1 (en) * 2001-03-07 2004-07-22 Webster G. R. Barrie Conversion of cbd to delta8-thc and delta9-thc
US20040110827A1 (en) * 2002-12-04 2004-06-10 Haim Aviv High enantiomeric purity dexanabinol for pharmaceutical compositions
US20040186166A1 (en) * 2002-12-19 2004-09-23 Burstein Sumner H. Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
US20050009903A1 (en) * 2003-06-10 2005-01-13 Martin Billy R. CB2-selective cannabinoid analogues
US20100035978A1 (en) * 2005-11-01 2010-02-11 Gw Pharma Limited Combination of cannabinoids for the treatment of peripheral neuropathic pain
US20120309820A1 (en) * 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109715152A (zh) * 2016-04-29 2019-05-03 柯巴斯医药有限公司 医治感染的方法

Also Published As

Publication number Publication date
JP6689078B2 (ja) 2020-04-28
JP2021185166A (ja) 2021-12-09
US9820964B2 (en) 2017-11-21
EP2956133A4 (en) 2016-12-21
US9801849B2 (en) 2017-10-31
US20150141501A1 (en) 2015-05-21
KR20190139327A (ko) 2019-12-17
US10369131B2 (en) 2019-08-06
US10154986B2 (en) 2018-12-18
AU2014216440B2 (en) 2018-08-09
AU2018258159B2 (en) 2020-01-02
WO2014127016A2 (en) 2014-08-21
AU2014216440A1 (en) 2015-08-20
CN110946854A (zh) 2020-04-03
AU2018258159A1 (en) 2018-11-22
KR20160002709A (ko) 2016-01-08
US20170071900A1 (en) 2017-03-16
US20180177757A1 (en) 2018-06-28
US20170071899A1 (en) 2017-03-16
CA2900982A1 (en) 2014-08-21
US20220117931A1 (en) 2022-04-21
JP2016510340A (ja) 2016-04-07
EP3851101A1 (en) 2021-07-21
BR112015019180A8 (pt) 2018-01-30
CA2900982C (en) 2021-06-01
JP2019031505A (ja) 2019-02-28
EP2956133A2 (en) 2015-12-23
US20190091200A1 (en) 2019-03-28
US11052066B2 (en) 2021-07-06
US20200093784A1 (en) 2020-03-26
US10085964B2 (en) 2018-10-02
WO2014127016A3 (en) 2015-11-26
US20170071898A1 (en) 2017-03-16
BR112015019180A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
US11052066B2 (en) Ultrapure tetrahydrocannabinol-11-oic acids
TW200825094A (en) Therapeutic pyrazolyl thienopyridines
WO2017189613A1 (en) Methods of using fasn inhibitors
ITMI962385A1 (it) Diaril-ciclometilenpirazoli farmacologicamente attivi procedimento per prepararli e composizioni farmaceutiche che li contengono
EP2488032B1 (en) Prostaglandin transporter inhibitors and uses thereof
US11028111B2 (en) Compound for treating metabolic diseases and preparation method and use thereof
CN106928311B (zh) 柠檬苦素衍生物、其制备方法及医药用途
HK40026965A (en) Ultrapure tetrahydrocannabinol-11-oic acids
CN114929682B (zh) 苯并硫代吡喃酮类化合物的盐及其制备方法和用途
CN117242076A (zh) 基于噻吩的化合物及其作为bckdk抑制剂的用途
CN112851626B (zh) 一类左旋双环吗啉，其制备方法、药物组合物和应用
TW401415B (en) Enantiomerically pure (+)-liarozole
CN113666895B (zh) 卤代2-苯并[c]呋喃酮类化合物及其应用
US9745275B2 (en) Pain-related compound and medical composition
WO2025168119A1 (zh) 四唑类化合物、其药物组合物及其应用
NO781891L (no) Fremgangsmaate ved fremstilling av nye, terapeutisk aktive estere
TW200407123A (en) Combinations of atorvastatin and α1 adrenergic receptor antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160106

RJ01 Rejection of invention patent application after publication